Celgene Corp (CELG) 92.93 $CELG
Final Glance: Biotechnology companies
AP - Tue Sep 09, 7:15PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
How Bad Is This News for Celgene Corporation?
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 09, 12:45PM CDT
When it comes to approving new drugs, the U.K. has some of the globe's toughest price negotiators. The National Institute for Health and Care Excellence, or NICE, has been anything but kind to drugmakers hoping to roll out high-priced medicine in...
Midday Glance: Biotechnology companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Shares of CELG Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 09, 9:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 25.85% as of today's recent price of $93.05.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Stock Market News for September 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 9:10AM CDT
Benchmarks reversed early gains and settled in the red zone on Thursday due to a late sell-off in energy shares
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
Final Glance: Biotechnology companies
AP - Tue Sep 09, 7:15PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
How Bad Is This News for Celgene Corporation?
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 09, 12:45PM CDT
When it comes to approving new drugs, the U.K. has some of the globe's toughest price negotiators. The National Institute for Health and Care Excellence, or NICE, has been anything but kind to drugmakers hoping to roll out high-priced medicine in...
Midday Glance: Biotechnology companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Shares of CELG Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 09, 9:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 25.85% as of today's recent price of $93.05.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Stock Market News for September 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 9:10AM CDT
Benchmarks reversed early gains and settled in the red zone on Thursday due to a late sell-off in energy shares
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
